Company / SG&A Expense
CAPRICOR THERAPEUTICS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$23.7M
FY2025
5-year range
$7.6M / $23.7M
FY2021-FY2025
Trend
+59.3%
vs FY2024
Sector context
#196 of 213
Health Care
What the data says
Among 213 Health Care companies, CAPRICOR THERAPEUTICS, INC. is in the top 8% for sg&a expense. SG&A Expense has increased for 6 consecutive years, from $5M in FY2019 to $24M in FY2025.
Based on SEC 10-K filings.
$24M in FY2025 with a 5-year CAGR of +33.7%.
Increased from $13M to $24M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +31.4%
- 5-Year CAGR
- +33.7%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 213This company $23.7M Sector average $722.3M
▼
-96.7% below sector average
Key checks
Key Insights
- CAPRICOR THERAPEUTICS, INC.'s sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +33.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 59.3% year-over-year.
- Ranks #196 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.7M | +59.3% |
| FY2024 | $14.9M | +16.1% |
| FY2023 | $12.8M | +22.8% |
| FY2022 | $10.4M | +37.0% |
| FY2021 | $7.6M | +37.3% |
| FY2020 | $5.5M | +12.4% |
| FY2019 | $4.9M | +0.0% |
| FY2018 | $4.9M | +3.5% |
| FY2017 | $4.8M | -3.5% |
| FY2016 | $4.9M | +12.8% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026